海思科：HSK39004吸入粉雾剂临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its new drug HSK39004, which is aimed at treating chronic obstructive pulmonary disease [1] Group 1: Company Developments - The company's subsidiaries, Tibet Haishi Pharmaceutical Co., Ltd. and Sichuan Haishi Pharmaceutical Co., Ltd., have been granted the Clinical Trial Approval Notice for HSK39004 [1] - HSK39004 is a novel targeted small molecule inhibitor developed independently by the company, possessing its own intellectual property rights [1] Group 2: Product Information - HSK39004 is intended for the treatment of chronic obstructive pulmonary disease [1] - The drug has met the relevant requirements for drug registration as per the review conducted by the National Medical Products Administration [1]